Raymond Murray Dawson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raymond Murray Dawson has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Chun-Qiang Liu
5 shared publicationsM. R. Alderton
Platforms Sciences Laboratory, Defence Science and Technology Organisation, PO Box 4331, Melbourne VIC 3001, Australia
2 shared publicationsB. M. Paddle
Aeronautical and Maritime Research Laboratory, Defence Science and Technology Organization, PO Box 4331, Melbourne, Victoria 3001, Australia
1 shared publicationChun‐Qiang Liu
DSTO Melbourne, Defence Science and Technology Organisation, PO Box 4331, Melbourne, VIC 3001, Australia
1 shared publicationD. Wells
CSIRO Molecular and Health Technologies, Private Bag 10, Clayton South VIC 3169, Australia
1 shared publicationH.R. Rose
DSTO Melbourne, PO Box 4331, Melbourne VIC 3001, Australia
1 shared publication
Latest Publications
- 1 September 2011
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 38 (3) , 237-242
Potent antimicrobial peptides with selectivity for Bacillus anthracis over human erythrocytes
- 1 September 2011
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 38 (3) , 237-242
Potent antimicrobial peptides with selectivity for Bacillus anthracis over human erythrocytes
- 1 May 2011
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 37 (5) , 432-437
Analogues of peptide SMAP-29 with comparable antimicrobial potency and reduced cytotoxicity
- 1 May 2011
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 37 (5) , 432-437
Analogues of peptide SMAP-29 with comparable antimicrobial potency and reduced cytotoxicity
- 15 October 2010
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 36 (6) , 579-580
Disulphide bonds of the peptide protegrin-1 are not essential for antimicrobial activity and haemolytic activity
- 15 October 2010
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 36 (6) , 579-580
Disulphide bonds of the peptide protegrin-1 are not essential for antimicrobial activity and haemolytic activity
- 1 October 2010
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 36 (4) , 359-363
Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis
- 1 October 2010
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 36 (4) , 359-363
Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis
- 6 October 2009
- Published by Wiley in Drug Development Research
- Vol. 70 (7) , 481-498
Cathelicidin peptide SMAP‐29: comprehensive review of its properties and potential as a novel class of antibiotics
Sheep myeloid antimicrobial peptide of 29 amino acids (SMAP‐29) is one of the most potent antimicrobial peptides known, with a broad spectrum of activity against bacteria, fungi, and viruses. It has also been shown to prevent infections in animals. SMAP‐29 is an α‐helical cathelicidin that acts rapidly to permeabilize membranes of susceptible organisms. However, it is also cytotoxic and hemolytic to mammalian cells. In this review, all published data on inhibition constants and hemolytic activities of SMAP‐29 are brought together for the first time, including data for the peptide of 28 residues that lacks the C‐terminal glycine and that also has the new C‐terminal residue amidated. Both peptides have been called SMAP‐29 in the literature. Antimicrobial activity of SMAP‐29 variants (including ovispirins) against Gram‐positive bacteria is also comprehensively tabulated, and anomalies in the nomenclature of the ovispirins are highlighted. The secondary structure, mode of action, and structure–activity relationships of SMAP‐29 are outlined, and the properties that indicate its therapeutic potential are identified; these are its broad‐spectrum antimicrobial activity with high potency, rapid biocidal action, limited development of bacterial resistance, synthesis by recombinant technology, ability to bind lipopolysaccharide, and demonstrated protection against infection in animal models. The limitations of SMAP‐29 are its high cytotoxicity and hemolytic activity, reduced activity under physiological conditions, and limited evidence for synergistic effects in combination with conventional antibiotics. Strategies with the potential to improve the selectivity toward pathogenic microorganisms over mammalian cells have been devised by the authors and are outlined. Drug Dev Res 70: 481–498, 2009. © 2009 Commonwealth of Australia; Published 2009 Wiley‐Liss, Inc.
- 6 October 2009
- Published by Wiley in Drug Development Research
- Vol. 70 (7) , 481-498
Cathelicidin peptide SMAP‐29: comprehensive review of its properties and potential as a novel class of antibiotics
Sheep myeloid antimicrobial peptide of 29 amino acids (SMAP‐29) is one of the most potent antimicrobial peptides known, with a broad spectrum of activity against bacteria, fungi, and viruses. It has also been shown to prevent infections in animals. SMAP‐29 is an α‐helical cathelicidin that acts rapidly to permeabilize membranes of susceptible organisms. However, it is also cytotoxic and hemolytic to mammalian cells. In this review, all published data on inhibition constants and hemolytic activities of SMAP‐29 are brought together for the first time, including data for the peptide of 28 residues that lacks the C‐terminal glycine and that also has the new C‐terminal residue amidated. Both peptides have been called SMAP‐29 in the literature. Antimicrobial activity of SMAP‐29 variants (including ovispirins) against Gram‐positive bacteria is also comprehensively tabulated, and anomalies in the nomenclature of the ovispirins are highlighted. The secondary structure, mode of action, and structure–activity relationships of SMAP‐29 are outlined, and the properties that indicate its therapeutic potential are identified; these are its broad‐spectrum antimicrobial activity with high potency, rapid biocidal action, limited development of bacterial resistance, synthesis by recombinant technology, ability to bind lipopolysaccharide, and demonstrated protection against infection in animal models. The limitations of SMAP‐29 are its high cytotoxicity and hemolytic activity, reduced activity under physiological conditions, and limited evidence for synergistic effects in combination with conventional antibiotics. Strategies with the potential to improve the selectivity toward pathogenic microorganisms over mammalian cells have been devised by the authors and are outlined. Drug Dev Res 70: 481–498, 2009. © 2009 Commonwealth of Australia; Published 2009 Wiley‐Liss, Inc.
- 1 January 2009
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 59 (1) , 50-55
The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor
- 1 January 2009
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 59 (1) , 50-55
The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor
- 1 September 2008
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 157 (2-3) , 308-314
Degradation of nerve agents by an organophosphate-degrading agent (OpdA)
- 1 September 2008
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 157 (2-3) , 308-314
Degradation of nerve agents by an organophosphate-degrading agent (OpdA)
- 1 January 2008
- Published by Taylor & Francis in Critical Reviews in Microbiology
- Vol. 34 (2) , 89-107
Properties and Applications of Antimicrobial Peptides in Biodefense Against Biological Warfare Threat Agents
Recent advances in knowledge of the properties of antimicrobial peptides (AMPs) are reviewed. AMPs are typically small, positively charged, amphipathic peptides that interact electrostatically and non-stereospecifically with the bacterial cell membrane, resulting in its permeabilization and cell death. Classes of AMPs, their mechanisms of action, hemolytic activity, and cytotoxicity towards host cells are discussed. A particular focus is AMPs with potential for use in defense against biological warfare agents. Some AMPs cytotoxic to Bacillus anthracis have been described. Synthesis of these peptides in multivalent form leads to a synergistic increase in antibacterial activity. Strategies to enhance the potency, stability, and selectivity of AMPs are discussed.
- 1 January 2008
- Published by Taylor & Francis in Critical Reviews in Microbiology
- Vol. 34 (2) , 89-107
Properties and Applications of Antimicrobial Peptides in Biodefense Against Biological Warfare Threat Agents
Recent advances in knowledge of the properties of antimicrobial peptides (AMPs) are reviewed. AMPs are typically small, positively charged, amphipathic peptides that interact electrostatically and non-stereospecifically with the bacterial cell membrane, resulting in its permeabilization and cell death. Classes of AMPs, their mechanisms of action, hemolytic activity, and cytotoxicity towards host cells are discussed. A particular focus is AMPs with potential for use in defense against biological warfare agents. Some AMPs cytotoxic to Bacillus anthracis have been described. Synthesis of these peptides in multivalent form leads to a synergistic increase in antibacterial activity. Strategies to enhance the potency, stability, and selectivity of AMPs are discussed.
- 1 May 2006
- Published by Wiley in Journal of Applied Toxicology
- Vol. 26 (3) , 247-252
Monovalent and polyvalent carbohydrate inhibitors of ricin binding to a model of the cell-surface receptor
A selection of galactose and lactose analogues was evaluated for their potency in inhibiting the binding of ricin to immobilised asialofetuin, which is a model of the cell‐surface receptor for ricin. The aim was to identify compounds that could be used as antagonists of ricin toxicity in vivo, and as more selective, and therefore safer, antitoxins. Although one of these analogues had been identified by molecular modelling in a previous study as a potentially potent inhibitor, it and the other carbohydrates studied were less effective than galactose and lactose themselves (I50 = 1.39 and 0.74 mm, respectively). In an attempt to increase the potency of carbohydrate‐based inhibitors, galactose was coupled to the surface of dendrimers. No synergistic interactions were observed from this multivalent approach. Encouraging results, however, were obtained with a self‐assembled lyotropic mesophase gel containing novel synthetic galactose‐based surfactants, which was able to sequester ricin from aqueous solution in a 2‐phase system. © Crown Copyright 2006. Reproduced with the permission of the Controller of HMSO. Published by John Wiley & Sons, Ltd.
- 1 May 2006
- Published by Wiley in Journal of Applied Toxicology
- Vol. 26 (3) , 247-252
Monovalent and polyvalent carbohydrate inhibitors of ricin binding to a model of the cell-surface receptor
A selection of galactose and lactose analogues was evaluated for their potency in inhibiting the binding of ricin to immobilised asialofetuin, which is a model of the cell‐surface receptor for ricin. The aim was to identify compounds that could be used as antagonists of ricin toxicity in vivo, and as more selective, and therefore safer, antitoxins. Although one of these analogues had been identified by molecular modelling in a previous study as a potentially potent inhibitor, it and the other carbohydrates studied were less effective than galactose and lactose themselves (I50 = 1.39 and 0.74 mm, respectively). In an attempt to increase the potency of carbohydrate‐based inhibitors, galactose was coupled to the surface of dendrimers. No synergistic interactions were observed from this multivalent approach. Encouraging results, however, were obtained with a self‐assembled lyotropic mesophase gel containing novel synthetic galactose‐based surfactants, which was able to sequester ricin from aqueous solution in a 2‐phase system. © Crown Copyright 2006. Reproduced with the permission of the Controller of HMSO. Published by John Wiley & Sons, Ltd.
- 24 January 2005
- Published by Wiley in Journal of Applied Toxicology
- Vol. 25 (1) , 30-38
Characterization of the binding of cholera toxin to ganglioside GM1 immobilized onto microtitre plates
Ganglioside GM1 is the receptor for cholera toxin on cell surfaces, and the binding of cholera toxin to GM1 immobilized on microtitre plates has been reported previously by several authors as an assay for the toxin (GM1‐ELISA). This assay has been examined in detail. Results were independent of the adsorption solvent for GM1 (methanol or phosphate‐buffered saline), the pH of aqueous solvents (7.4–10.2) and the temperature (4–37 °C). High and near‐maximal rates of absorbance change in the assay were found for lower concentrations of GM1 (100 ng ml−1) and for shorter incubation times (a few hours) than reported in the literature. A method was devised to provide a semi‐quantitative estimate of the amount of GM1 bound to the plate; this was found to be in the low nanogram range. Binding of cholera toxin to the immobilized GM1 required ≥1.5 h for maximal assay results. The failure of free GM1 in solution to displace cholera toxin once bound to immobilized GM1 indicated that binding to immobilized GM1 is irreversible in the time frame of the experiment. Data from the literature support the very slow dissociation rates of the toxin–GM1 complex. Copyright © 2005 John Wiley & Sons, Ltd.
- 24 January 2005
- Published by Wiley in Journal of Applied Toxicology
- Vol. 25 (1) , 30-38
Characterization of the binding of cholera toxin to ganglioside GM1 immobilized onto microtitre plates
Ganglioside GM1 is the receptor for cholera toxin on cell surfaces, and the binding of cholera toxin to GM1 immobilized on microtitre plates has been reported previously by several authors as an assay for the toxin (GM1‐ELISA). This assay has been examined in detail. Results were independent of the adsorption solvent for GM1 (methanol or phosphate‐buffered saline), the pH of aqueous solvents (7.4–10.2) and the temperature (4–37 °C). High and near‐maximal rates of absorbance change in the assay were found for lower concentrations of GM1 (100 ng ml−1) and for shorter incubation times (a few hours) than reported in the literature. A method was devised to provide a semi‐quantitative estimate of the amount of GM1 bound to the plate; this was found to be in the low nanogram range. Binding of cholera toxin to the immobilized GM1 required ≥1.5 h for maximal assay results. The failure of free GM1 in solution to displace cholera toxin once bound to immobilized GM1 indicated that binding to immobilized GM1 is irreversible in the time frame of the experiment. Data from the literature support the very slow dissociation rates of the toxin–GM1 complex. Copyright © 2005 John Wiley & Sons, Ltd.